Denmark-based Genmab A/S announced positive topline data from the second part of the Phase III CASSIOPEIA trial evaluating daratumumab (marketed as Darzalex) monotherapy as maintenance treatment compared to observation for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant.
AbbVie’s Rinvoq (upadacitinib) as a monotherapy hit both primary and all secondary endpoints in a second Phase III trial, Measure Up 2, in patients with moderate to severe atopic dermatitis.
Merck’s Keytruda Approved for First-Line Treatment of Colorectal CancerApprovals, Blockbusters, Checkpoint Inhibitors, Clinical Data, FDA, FDA/Regulatory, Microsatellite instability-high (MSI-H) cancer, Microsatellite Instability-High (MSI-H) Colorectal Cancer, Mismatch Repair Deficient (dMMR) Colorectal Cancer, Monotherapy, New Indications, PD-1/PD-L1 inhibitors, Progression-Free Survival (PFS), Therapeutics
The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
The U.S. Food and Drug Administration approved Clovis Oncology Inc.’s drug Rubraca for the treatment of adult patients with metastatic castration-resistant prostate cancer, whose tumors have a genetic mutation.
Exploratory Analysis Shows Significant OS Results from Keytruda in KRAS MutationsBlockbusters, Checkpoint Inhibitors, Chemotherapy, Clinical Trials, European Society for Medical Oncology (ESMO), Exploratory Analysis, Keytruda, KRAS Mutations, Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Monotherapy, Overall Response Rate (ORR), Overall Survival (OS), Progression-Free Survival (PFS), R&D
Findings from the Phase III KEYNOTE-042 study show improvements in overall survival (OS), PFS and ORR in patients treated with Merck’s Keytruda (pembrolizumab) as a monotherapy.
The U.S. Food and Drug Administration approved the anti-PD-1 therapy Keytruda as a monotherapy for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 with disease progression after one or more previous lines of systemic therapy.